UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 46.23% | 29.72% | -40.87% | -49.51% | -35.80% |
| Total Depreciation and Amortization | 31.19% | 121.90% | 140.23% | 126.62% | 41.60% |
| Total Amortization of Deferred Charges | -- | -- | -204.88% | 204.88% | -- |
| Total Other Non-Cash Items | 96.67% | -45.08% | 31.71% | -60.65% | -1.41% |
| Change in Net Operating Assets | -1,063.19% | -209.87% | -54.73% | 111.66% | 31.30% |
| Cash from Operations | -7.83% | -181.41% | -52.80% | -67.70% | -32.42% |
| Capital Expenditure | -22.73% | 85.22% | 9.38% | -67.86% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 20.39% | -54.34% | 129.52% | 136.28% | -291.74% |
| Cash from Investing | 20.32% | -54.28% | 129.41% | 136.76% | -292.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 426.47% | 46,623.94% | -45.28% | -99.64% | -99.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -99.98% | -- |
| Cash from Financing | 191,676.47% | 44,007.04% | -79.11% | -99.70% | -99.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.82% | -56.01% | 97.26% | -112.56% | -286.48% |